Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Base Year
Historical Year
Forecast Year
Nucleic acid therapeutics utilize either synthetic or natural nucleic acids to control gene expression and address multiple ailments. ASOs, siRNAs, miRNAs, aptamers, and CRISPR/Cas9 are some of the common technologies used in this treatment. They provide a focused method for managing diseases, enabling accurate genetic intervention, particularly helpful for diseases with identifiable genetic causes like rare genetic disorders, cancers, and viral infections.
Increasing Prevalence of Genetic Disorders and Chronic Diseases Boost the Market Growth
The rising prevalence of genetic disorders, and other diseases, such as cystic fibrosis, muscular dystrophy, cancer, cardiovascular diseases, metabolic syndrome, and others are the primary factors boosting the market growth. Aberrations of DNA sequences and gene expression are often observed in these indications, for which nucleic acid therapies are a suitable solution, providing effective treatment to a wider section of the population. This is leading to an increased application of nucleic acid therapeutics, intended to combat the burden of rising morbidities.
Advancements in Genomic Technologies and Personalized Medicine to Meet Rising Nucleic Acid Therapeutics Market Demand
Advanced technologies in nucleic acid therapeutics include NGS, CRISPR/Cas9 gene editing, and bioinformatics which has further advanced the progress of these therapeutics. This makes it easier to diagnose the mutation in genes and get the right treatment for the individuals affected. The market growth is driven by the increasing demand for personalized treatments, where treatments and medications are based on a person’s genetic profile.
Increase in Clinical Trial and Research Initiatives
In August 2023, CureVac N.V. and GSK initiated a Phase 2 trial in Australia for their single and double-modified mRNA COVID-19 vaccine candidates. The study's goal is to evaluate the safety, reactogenicity, and immune responses in 415 healthy adults after successful Phase 1 results for a comparable vaccine designed for the omicron BA.1 variant.
In March 2022, Moderna, Inc. tested an experimental HIV trimer mRNA vaccine (mRNA-1574) in around 100 HIV-negative adults in a Phase 1 clinical trial. The NIAID-sponsored trial within the NIH aimed to evaluate the safety and immunogenicity of the vaccine. An NIAID grant funded the development of the vaccine, with assistance from Scripps Research and IAVI.
Integration with Nanotechnology Enhancing Market Growth
Nanotechnology is expanding the market through improvements in the delivery, stability, and performance of nucleic acid therapeutic agents. The use of lipid nanoparticles for delivery of siRNAs and mRNA vaccines in order to resist the degradation of nucleic acids is amongst the major market trends.
Expanding Applications in Oncology Boosting Market Adoption
Nucleic acid therapeutics are being increasingly employed in oncology because they can address specific cancer-related genes and signaling cascades. Techniques like antisense oligonucleotides, small interfering RNA (siRNAs), and CRISPR/Cas9 are being employed to silence oncogenes and related mutations. Such advancements are anticipated to revolutionize precision oncology, by offering personalized treatments.
Regulatory Approvals and Collaborations Enhancing Market Expansion
The nucleic acid therapeutics market is expanding due to the approval and collaborations through existing agencies such as the FDA and EMA. New drugs include Spinraza, a spinal muscular atrophy treatment, and Onpattro for transthyretin-mediated hereditary amyloidosis. These affiliations are expected to enhance the rate of development of more therapies and innovation. In September 2022, Alnylam Pharmaceuticals received the marketing approval for AMVUTTRA by the European Commission. It is an RNAi therapy for adults with stage 1 or 2 polyneuropathy caused by hereditary transthyretin-mediated amyloidosis. The authorization comes after promising 18-month findings from the HELIOS-A Phase 3 trial, with more than half of patients experiencing a stop or improvement in polyneuropathy symptoms. AMVUTTRA provides subcutaneous administration every three months or possibly twice a year.
Increasing Investment in Research and Development Driving Market Growth
The market is growing because of increased funding for research and development. There is a focus on investing in the development and identification of new drugs by pharmaceutical enterprises, biotechnology businesses, and educational establishments. It is also supported by government funding and grants for such enhancing initiatives and holds great promise for genetic disorders, cancers, chronic diseases, and others.
Market Breakup by Product Type
Market by Indication
Market Breakup by End User
Market Breakup by Region
Market Segmentation Based on End User Set to Witness Substantial Growth
Based on the end user, the market is divided into hospitals, research and academic institutes, and others. Among these, the market is expected to be dominated by research laboratories due to the rising demand for nucleic acid research and treatment interventions. These labs discover new medications and technologies, thereby nurturing new ideas for broadening their applications. Due to the tremendous interest in genetics and molecular targeted therapies, more research institutes and biotechnology companies are anticipated to adopt these technologies and impact the market landscape significantly.
Nucleic Acid Therapeutics Market Analysis by Region
Based on regions, the market report covers North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America is expected to dominate the market, driven by an immense focus on providing investments to conduct research. In addition, the presence of technically advanced infrastructure also impacts the market value positively.
European nucleic acid market comes next as a region with high regard for innovation, and noteworthy support from the healthcare regulatory authorities, aiding the implementation of neurotechnology. Growth in developing countries, especially in Asia Pacific, due to economic development, higher healthcare expenditure, and a rising population of patients suffering from genetic and chronic diseases, is encouraging market growth.
The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Copernicus Therapeutics Inc.
Established in 1995 and headquartered in Ticino, Switzerland, the company has a diversified product line concerning nucleic acid therapeutics. This clinical stage biopharmaceutical company has a key emphasis on leveraging gene therapy to treat rare diseases.
Silence Therapeutics PLC
Founded in 1994, the company has a presence across the United States, United Kingdom and other parts of Europe. The company is building a robust siRNAs-based pipeline for various diseases including rare diseases like Polycythemia Vera (PV) and other cardiovascular diseases. It is focused on using its mRNAi GOLD™ platform to develop innovative technologies for precise drug development.
Other companies include Sanofi S.A., Thermo Fisher Scientific Inc., Sarepta Therapeutics, Inc., Novartis AG, Merck & Co., Inc., Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and Arrowhead Pharmaceuticals, Inc.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us today for customized, data-driven solutions tailored to your unique requirements!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Product Type |
|
Breakup by Indication |
|
Breakup by End User |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124